Collaboration on possible treatments for Alzheimer’s
Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a symptomatic treatment for Alzheimer’s disease and other cognitive disorders. Under the terms of the agreement, Selvita will be responsible for identification of a lead compound within the SEL103 programme, while Orion will take over pre-clinical and clinical development as well as further commercialisation costs. The collaboration combines Orion’s experience in CNS research and development with Selvita’s know-how in discovery chemistry and biology assays. Details on the amounts of up-front payments, research funding or milestones to Selvita were not available. Selvita’s SEL103 programme is based on novel, orally bioavailable and highly selective small molecules that have the potential to play a role in the treatment of multiple cognitive disorders, including Alzheimer’s disease or dementia.